Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Leal Therapeutics is developing first-in-class therapeutics to correct metabolic imbalances in the brain for treatment of high unmet…